QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Philip M Arlen, M.D.
Precision Biologics, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moffitt Cancer Center
Tampa, Florida, United States
- Johns Hopkins Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
- Washington University in St. Louis
St Louis, Missouri, United States
- Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2012
- Primary completion
- 31 Mar 2017
- Completion
- 31 Mar 2017
- Last update posted
- 4 Aug 2017
- Registered enrollment
- 94
- Registry id
- NCT01040000
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.